Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

BACKGROUND: Cisplatin is the most commonly used chemotherapeutic agent in the treatment of patients with metastatic and/or recurrent urothelial cancer. However, the effectiveness of these treatments is severely limited due to the development of cisplatin resistance. Cancer stem cells have been docum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Hagiwara, Masayuki, Kikuchi, Eiji, Tanaka, Nobuyuki, Kosaka, Takeo, Mikami, Shuji, Saya, Hideyuki, Oya, Mototsugu
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5793458/
https://ncbi.nlm.nih.gov/pubmed/29385995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-3988-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados